S&P 500
7,361.40
-2.92%
Dow Jones
50,740.20
-1.68%
Nasdaq 100
28,798.10
-5.22%
Russell 2000
2,815.42
-3.98%
FTSE 100
10,343.60
-0.51%
Nikkei 225
63,838.20
-5.58%

Investing

VERV logo Verve Therapeutics : VERV

VERV

Stock Data

$11.13

Change up

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Verve Therapeutics Inc is a pioneering company in the field of genetic medicines, focusing on developing gene editing treatments for cardiovascular diseases. With a flagship product, VERVE-101, designed to permanently disable the PCSK9 gene in the liver, the company aims to revolutionize the treatment of heart diseases. Additionally, it works on other promising gene targets like ANGPTL3. Based in Cambridge, Massachusetts, and founded in 2018, Verve collaborates with notable institutions like Beam Therapeutics Inc., Acuitas Therapeutics, Inc., and The Broad Institute to advance its mission.

All Verve Therapeutics Articles

1 Article